Aldeyra Therapeutics, Inc (NASDAQ:ALDX) CEO Todd C. Brady acquired 14,288 shares of the business’s stock in a transaction dated Wednesday, September 18th. The stock was purchased at an average price of $5.91 per share, with a total value of $84,442.08. Following the completion of the transaction, the chief executive officer now directly owns 614,826 shares of the company’s stock, valued at approximately $3,633,621.66. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Todd C. Brady also recently made the following trade(s):
- On Monday, September 9th, Todd C. Brady bought 10,000 shares of Aldeyra Therapeutics stock. The shares were bought at an average price of $4.89 per share, with a total value of $48,900.00.
Shares of Aldeyra Therapeutics stock opened at $5.74 on Friday. The company’s fifty day simple moving average is $5.19 and its two-hundred day simple moving average is $6.66. Aldeyra Therapeutics, Inc has a 12-month low of $4.31 and a 12-month high of $14.30.
Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.49) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $0.02. On average, analysts forecast that Aldeyra Therapeutics, Inc will post -2.01 earnings per share for the current year.
A number of institutional investors have recently made changes to their positions in the stock. Private Advisors LLC lifted its stake in Aldeyra Therapeutics by 50.4% during the 1st quarter. Private Advisors LLC now owns 33,151 shares of the biotechnology company’s stock valued at $299,000 after acquiring an additional 11,112 shares during the period. Point72 Asset Management L.P. bought a new position in Aldeyra Therapeutics during the 2nd quarter valued at about $1,950,000. Strs Ohio lifted its stake in Aldeyra Therapeutics by 7.5% during the 2nd quarter. Strs Ohio now owns 71,900 shares of the biotechnology company’s stock valued at $431,000 after acquiring an additional 5,000 shares during the period. Ironwood Investment Management LLC purchased a new stake in shares of Aldeyra Therapeutics during the 1st quarter valued at about $116,000. Finally, National Asset Management Inc. increased its position in shares of Aldeyra Therapeutics by 69.4% during the 1st quarter. National Asset Management Inc. now owns 27,006 shares of the biotechnology company’s stock valued at $244,000 after purchasing an additional 11,066 shares during the last quarter. Institutional investors own 61.26% of the company’s stock.
Several research analysts have commented on ALDX shares. ValuEngine raised shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, September 10th. Cantor Fitzgerald set a $33.00 target price on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Finally, Zacks Investment Research downgraded shares of Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 14th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Aldeyra Therapeutics currently has an average rating of “Buy” and an average price target of $24.19.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Featured Article: Example of operating income, EBIT and EBITDA
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.